Adverse events associated with nevirapine use in pregnancy: A systematic review and meta-analysis

AIDS

Volumn 27, Issue 7, 2013, Pages 1135-1143

  Ford, Nathan ^a,b   Calmy, Alexandra ^a,c   Andrieux Meyer, Isabelle ^a   Hargreaves, Sally ^d   Mills, Edward J ^e   Shubber, Zara ^f  

^a MÉDECINS SANS FRONTIÈRES   (Switzerland)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^d HAMMERSMITH HOSPITAL   (United Kingdom)

^e UNIVERSITY OF OTTAWA   (Canada)

^f IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Adverse events; Hepatotoxicity; Nevirapine; Pregnancy; Rash; Safety

Indexed keywords

NEVIRAPINE;

CD4 LYMPHOCYTE COUNT; DRUG HYPERSENSITIVITY; DRUG USE; DRUG WITHDRAWAL; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; META ANALYSIS; PREGNANT WOMAN; PRIORITY JOURNAL; RASH; REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW; TREATMENT WITHDRAWAL;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; FEMALE; HIV SEROPOSITIVITY; HUMANS; NEVIRAPINE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; RISK ASSESSMENT;

EID: 84879092428     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32835e0752     Document Type: Review

References (34)

1. Anon. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. Geneva: WHO; 2010.
2. Hitti J, Frenkel LM, Stek AM, Nachman SA, Baker D, GonzalezGarcia A, et al. Maternal toxicity with continuous nevirapine in pregnancy: results from PACTG 1022. J Acquir Immune Defic Syndr 2004; 36:772-776.
3. Jamisse L, Balkus J, Hitti J, Gloyd S, Manuel R, Osman N, et al. Antiretroviral-associated toxicity among HIV-1-seropositive pregnant women in Mozambique receiving nevirapine-based regimens. J Acquir Immune Defic Syndr 2007; 44:371-376.
4. Peters PJ, Polle N, Zeh C, Masaba R, Borkowf CB, Oyaro B, et al. Nevirapine-Associated Hepatotoxicity and Rash among HIV-Infected Pregnant Women in Kenya. J Int Assoc Physicians AIDS Care (Chic) 2012; 11:142-149.
5. Coffie PA, Tonwe-Gold B, Tanon AK, Amani-Bosse C, Bedikou G, Abrams EJ, et al. Incidence and risk factors of severe adverse events with nevirapine-based antiretroviral therapy in HIV-infected women. MTCT-Plus program, Abidjan, Cote d'Ivoire. BMC Infect Dis 2010; 10:188.
6. Anon. Antiretroviral drugs for treating pregnant women and preventing HIV infections in infants. Recommendations for a public health approach. Geneva: WHO; 2010.
7. Anon. Use of antiretroviral drugs for treating pregnant women and preventing HIV infection in infants. Programmatic update. Geneva: WHO; 2012.
8. Moher DLA, Tetzlaff J, Altman DG, The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. PLoS Med 2009; 6:6.
9. Shubber Z, Calmy A, Andrieux-Meyer I, Vitoria M, Renaud-Thery F, Shaffer N, et al. Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis. AIDS 2013 [Epub ahead of print].
10. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336:924-926.
11. Freeman MF, Tukey JW. Transformations related to the angular and the square root. Ann Math Statist 1950; 21:607-611.
12. Sheehe PR. Combination of log relative risk in retrospective studies of disease. Am J Public Health Nations Health 1966; 56:1745-1750.
13. Fleiss JL. The statistical basis of meta-analysis. Stat Methods Med Res 1993; 2:121-145.
14. Golder S, Loke YK, Bland M. Meta-analyses of adverse effects data derived from randomised controlled trials as compared to observational studies: methodological overview. PLoS Med 2011; 8:e1001026.
15. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327:557-560.
16. Kilewo C, Karlsson K, Massawe A, Lyamuya E, Swai A, Mhalu F, et al. Prevention of mother-to-child transmission of HIV-1 through breast-feeding by treating infants prophylactically with lamivudine in Dar es Salaam, Tanzania: the Mitra Study. J Acquir Immune Defic Syndr 2008; 48:315-323.
17. Phanuphak N, Apornpong T, Teeratakulpisarn S, Chaithong-wongwatthana S, Taweepolcharoen C, Mangclaviraj S, et al. Nevirapine-associated toxicity in HIV-infected Thai men and women, including pregnant women. HIV Med 2007; 8:357-366.
18. van Schalkwyk JE, Alimenti A, Khoo D, Maan E, Forbes JC, Burdge DR, et al. Serious toxicity associated with continuous nevirapine-based HAART in pregnancy. BJOG 2008; 115:1297-1302.
19. Aaron E, Kempf MC, Criniti S, Tedaldi E, Gracely E, Warriner A, et al. Adverse events in a cohort of HIV infected pregnant and nonpregnant women treated with nevirapine versus nonnevirapine antiretroviral medication. PLoS One 2010; 5:e12617.
20. Bersoff-Matcha SJ, Rourke D, Blank J. Evaluation of the safety of nevirapine therapy during pregnancy. J Acquir Immune Defic Syndr 2010; 54:560-562.
21. Black V, Hoffman RM, Sugar CA, Menon P, Venter F, Currier JS, et al. Safety and efficacy of initiating highly active antiretroviral therapy in an integrated antenatal and HIV clinic in Johannesburg, South Africa. J Acquir Immune Defic Syndr 2008; 49:276-281.
22. Bottaro EG, Huberman MJ, Iannella Mdel C, Vesperoni FA, Scapellato PG, Errea S, et al. Nevirapine-associated toxicity in clinical practice in Buenos Aires, Argentina. J Int Assoc Physicians AIDS Care (Chic) 2010; 9:306-312.
23. Joao EC, Calvet GA, Menezes JA, D'Ippolito MM, Cruz ML, Salgado LA, et al. Nevirapine toxicity in a cohort of HIV-1-infected pregnant women. Am J Obstet Gynecol 2006; 194:199-202.
24. Joy S, Poi M, Hughes L, Brady MT, Koletar SL, Para MF, et al. Third-trimester maternal toxicity with nevirapine use in pregnancy. Obstet Gynecol 2005; 106 (5 Pt 1):1032-1038.
25. Kondo W, Carraro EA, Prandel E, Dias JM, Perini J, Macedo RL, et al. Nevirapine-induced side effects in pregnant women: experience of a Brazilian university hospital. Braz J Infect Dis 2007; 11:544-548.
26. Lyons F, Hopkins S, Kelleher B, McGeary A, Sheehan G, Geoghegan J, et al. Maternal hepatotoxicity with nevirapine as part of combination antiretroviral therapy in pregnancy. HIV Med 2006; 7:255-260.
27. Marazzi MC, Germano P, Liotta G, Guidotti G, Loureiro S, da Cruz Gomes A, et al. Safety of nevirapine-containing antiretroviral triple therapy regimens to prevent vertical transmission in an African cohort of HIV-1-infected pregnant women. HIV Med 2006; 7:338-344.
28. Natarajan U, Pym A, McDonald C, Velisetty P, Edwards SG, Hay P, et al. Safety of nevirapine in pregnancy. HIV Med 2007; 8:64-69.
29. Snijdewind IJ, Smit C, Godfried MH, Nellen JF, de Wolf F, Boer K, et al. Hcv coinfection, an important risk factor for hepatotoxicity in pregnant women starting antiretroviral therapy. J Infect 2012; 64:409-416.
30. Weinberg A, Forster-Harwood J, Davies J, McFarland EJ, Pappas J, Kinzie K, et al. Safety and tolerability of antiretrovirals during pregnancy. Infect Dis Obstet Gynecol 2011; 2011:867674.
31. Zuk DM, Hughes CA, Foisy MM, Robinson JL, Singh AE, Houston S. Adverse effects of antiretrovirals in HIV-infected pregnant women. Ann Pharmacother 2009; 43:1028-1035.
32. Thomas TK, Masaba R, Borkowf CB, Ndivo R, Zeh C, Misore A, et al. Triple-antiretroviral prophylaxis to prevent mother-to-child HIV transmission through breastfeeding: the Kisumu Breastfeeding Study, Kenya: a clinical trial. PLoS Med 2011; 8:e1001015.
33. WHO. Technical update on treatment optimization. Use of efavirenz during pregnancy: a public health perspective. Geneva: WHO; June 2012.
34. Bera E, Mia R. Safety of nevirapine in HIV-infected pregnant women initiating antiretroviral therapy at higher CD4 counts: a systematic review and meta-analysis. SAMJ 2012; 11:855-859.